BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. BMC Cancer 2014; 14: 802.Chen, J. et al. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. BMC Cancer 14, 802 (2014)....
药物指导及病因判断的依据:据我们所知,我们报告了先进个证明 BRAF p.V600E 可以介导 ROS1 重排 NSCLC 中劳拉替尼耐药性的病例,并且ROS1 TKI联合dabrafenib和trametinib的靶向治疗可作为后续治疗的有效治疗选择。关键词:BRAF V600E;非小细胞肺癌; ROS1重排;案例报告;劳拉替尼联合达拉非尼和曲美替尼。 癌症靶向药...
colon cancer,with a BRAF V600E mutation detected.This prompted a modification of the therapy regimen of cetuximab,dabrafenib and trametinib,which effectively held back the progression of penile metastasis in the patient.CONCLUSION Combining the BRAF/MEK-targeted therapy with cetuximab demonstrates a ...
Gastroonkologie Literatur kompakt mCRC mit BRAF-V600E-Mutation – gibt es bessere Optionen? Die bevorzugte Behandlung von Personen mit einem metastasierten kolorektalen Karzinom und BRAF- V600E-Mutation ist bislang Bevaci- zumab plus FOLFOXIRI. Ob ein anderer Antikörper wo...
KRAS mutation conferred a poorer disease-free survival (HR = 0.6, 95% CI 0.38–0.97). Conclusions The V600E BRAF mutation confers a worse prognosis to stage II and stage III colon cancer patients independently of disease stage and therapy....
Durable response to third-line combination therapy in a metastatic colorectal cancer patient with BRAF V600E mutation: A case report Search in:This JournalAnywhere Advanced search Human Vaccines & ImmunotherapeuticsVolume 21, 2025 -Issue 1 Submit an articleJournal homepage...
Immunotherapy - Cancer Durable response to third-line combination therapy in a metastatic colorectal cancer patient with BRAF V600E mutation: A case report Qun Zhang, Li Li & Xiaoping Qian Article: 2471058 | Received 08 Aug 2024, Accepted 19 Feb 2025, Published online: 25 Feb 2025 Cite this...
Since the publication of the TRIBE trial, therefore, the FOLFOXIRI bevacizumab regimen has been considered the preferred first-line treatment in fit patients with advanced BRAFV600-mutated CRC [18]. Role of BRAF Mutation BRAF was identified as an oncogene in human cancer and its mutations, which...
First-line triplet-drug therapy was associated with better OS, especially in patients with good physical condition and high tumor burden. Keywords Advanced colorectal cancer, BRAF V600E mutation, Propensity-score matching, Efficacy, Prognosis Introduction BRAF mutation leads to downstream ...
Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, ...